|
|
Volumn 2, Issue 1, 2002, Pages 20-24
|
|
Pharmacogenomic-guided drug development: Regulatory perspective
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CODEINE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DRUG METABOLIZING ENZYME;
HERCEPT;
IMATINIB;
OMEPRAZOLE;
TRASTUZUMAB;
WARFARIN;
ARTICLE;
CLINICAL TRIAL;
COHORT ANALYSIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DNA MICROARRAY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG RESPONSE;
DRUG SAFETY;
GENETIC DISORDER;
GENETIC VARIABILITY;
HUMAN;
PATIENT SELECTION;
PHARMACOGENOMICS;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
SIDE EFFECT;
CLINICAL TRIALS;
DRUG AND NARCOTIC CONTROL;
DRUG DESIGN;
GENOMICS;
HUMANS;
PHARMACOGENETICS;
|
|
EID: 0036367324
PISSN: 1470269X
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.tpj.6500046 Document Type: Article |
|
Times cited : (96)
|
|
References (4)
|
